We recommend that if individuals learn that they are infected with EBV, that they take Gene-Eden-VIR to reduce the danger posed by the latent Epstein Barr Virus. - Mike Evans, polyDNA
Rochester, NY (PRWEB) February 10, 2014
Studies have found a strong link between the Epstein Barr Virus (EBV) and more than 10% of all stomach cancers (1). As study authors wrote, “Results support a role of EBV in 10.67% of the GC (gastric carcinoma) cases (1).” The National Cancer Institute states that “in 2013, it is estimated 21,600 Americans will be diagnosed with gastric cancer and 10,990 persons will die of it.” (See Cancer.gov, last modified on December 13, 2013) (2). polyDNA recommends Gene-Eden-VIR to help the immune system target the latent EBV. This natural product was clinically proven to reduce symptoms of an Epstein Barr Virus infection in a study that followed FDA guidelines.
Research shows that younger men tend to have EBV linked stomach cancer, and in general, more men than women develop EBV related GC. As multiple studies found, “A recent meta-analysis (an analysis of many studies) showed that young patients are more likely to have EBV positive GCs (1).”
polyDNA recommends that individuals get tested for the presence of the Epstein Barr virus. “Laboratory testing can help distinguish whether someone is susceptible to EBV infection or has a recent or past infection. Healthcare providers can test for antibodies to the following EBV-associated antigens: Viral capsid antigen (VCA), Anti-VCA IgM appears early in EBV infection and usually disappears within 4 to 6 weeks, Anti-VCA IgG appears in the acute phase of EBV infection, peaks at 2 to 4 weeks after onset, declines slightly then persists for the rest of a person’s life. Early antigen (EA) Anti-EA IgG appears in the acute phase of illness and generally falls to undetectable levels after 3 to 6 months. In many people, detection of antibody to EA is a sign of active infection. However, 20% of healthy people may have antibodies against EA for years. EBV nuclear antigen (EBNA) Antibody to EBNA, determined by the standard immunofluorescent test, is not seen in the acute phase of EBV infection but slowly appears 2 to 4 months after onset of symptoms and persists for the rest of a person’s life. Other EBNA enzyme immunoassays may report false positive results.” (See the CDC’s page on EBV testing, last updated on January 7, 2014) (3).
“We recommend that if individuals learn that they are infected with EBV, that they take Gene-Eden-VIR to reduce the danger posed by the latent Epstein Barr Virus. This all natural remedy was proven to reduce symptoms associated with an EBV infection in a post-marketing clinical study.” – Mike Evans, polyDNA
A study published on August 12, 2013 in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs, showed that Gene-Eden-VIR reduced EBV symptoms. Study authors wrote that, “Individuals infected with the Epstein Barr Virus…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (4).” The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (4).”
To learn more about Gene-Eden-VIR, and EBV, visit http://gene-eden-kill-virus.com/EBV.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.
(1) Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Published on January 6, 2014.
(2) Systemic Lupus Erythematosus - Mechanisms of Disease. Published on February 28, 2008.
(3) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.